Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study;Efficacité et tolérance du cartéolol 1% à libération prolongée une fois par jour: Étude randomisée en double insu

Journal Francais d'Ophtalmologie

Volumn 26, Issue 2, 2003, Pages 131-136

  Trinquand, C ^a   Romanet, J P ^b   Nordmann, J P ^c   Allaire, C ^a  

^a Laboratoire Chauvin   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

Alginic acid; Carteolol; Glaucoma; Intraocular pressure

Indexed keywords

ACECLIDINE; ALGINIC ACID; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; LATANOPROST; LONG ACTING DRUG; PILOCARPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART RATE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; SLIT LAMP; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CARTEOLOL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION;

EID: 20244385516     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kitazawa Y, Azuma I, Takase M, Koememushi S. Ocular hypotensive effects of cartéolol hydrochloride in primary open-angle glaucoma and ocular hypertensive patients: a double-masked cross-over study for the determination of concentrations optimal for clinical use. Acta Soc Ophthalmol Jpn, 1981;85:798-804.
2. Keates EU, Friedland BR, Stewart RH et al. Cartéolol hydrochloride: controlled evaluations of its ocular hypotensive efficacy relative to its vehicle, and, in combination with pilocarpine, relative to timolol. J Glaucoma, 1993;3:315-22.
3. Maclure GM. Comparison of cartéolol and timolol: a double-blind study. European Glaucoma Society, Abstracts 1988; P32.
4. Stewart WC, Shields MB, Allen RC et al. A 3-month comparison of 1% and 2% cartéolol and 0.5% timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol, 1991;229:258-61.
5. Flammer J, Kitazawa Y, Bonomi L et al. Influence of cartéolol and timolol on IOP and visual fields in glaucoma: a multi-center, double-masked, prospective study. Eur J Ophthalmol 1992;2:169-74.
6. Blackwell B. Treatment adherence. Br J Psychiatry, 1976;129:513-31.
7. Evans LV. Mucilaginous substances from macroalgae: an overview. Symp Soc Exp Biol, 1989;43:455-61.
8. Washington N, Steele RJ, Jackson SJ et al. Patterns of food and acid reflux in patients with low-grade oesophagitis-the role of an anti-reflux agent. Aliment Pharmacol Ther, 1998;12:53-8.
9. Tissie G, Sebastian C, Maurin F et al. Evaluation of a novel cartéolol eye-drops with alginic acid as long action promoter. EVER Congress, Palma de Majorca, Spain. 10-4-2000.
10. Sechoy O, Chambaudy A, Trinquand CJ. LCM-1036 and LCM-1037 cartéolol solution (1% and 2%): new long acting formulations for the reduction of elevated intraocular pressure in rabbits. Invest Ophthalmol Vis Sci, 41, S572, Abstract Nr3035, 2000.
11. Sebastian C, Tissie G, Sechoy O et al. Alginic acid effect on ocular distribution of cartéolol after single instillation in pigmented rabbits. EVER Congress, Palma de Majorca, Spain, 10-4-2000.
12. Dupin O, Robert F, Trinquand C, Arnaud B. Comparison of 2% cartéolol long acting ophthalmic solution and 2% cartéolol eyedrops in healthy volunteers. EVER Congress, Palma de Majorca, Spain, 10-4-2000.
13. Rosenlund EF. The intraocular pressure lowering effect of timolol in gel-forming solution. Acta Ophthalmol Scand, 1996;74:160-2.
14. Grouin JM, Coste. Essais d'équivalence: méthodologie et analyse. In: Bouvenot G, Vray M, eds. Essais cliniques: théorie, pratique et critique. Paris: Flammarion, 1999.
15. Stewart WC. Cartéolol, an ophthalmic β-adrenergic blocker with intrinsic sympathomimetic activity. J Glaucoma, 1994;3:339-45.
16. Scoville B, Krieglstein GK, Then E et al. Measuring drug-induced eye irritation: a simple new clinical assay. J Clin Pharmacol, 1985;25:210-8.
17. Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of cartéolol and timolol in ocular hypertension. Am J Ophthalmol, 1988;105:150-4.
18. Novack GD, Leopold IH. The toxicity of topical ophthalmic beta-blockers. J Toxicol-Cut Ocular Toxicol, 1987;6:283-97.
19. Akingbehin T, Sunder Raj P. Ophthalmic topical beta blockers: Review of ocular and systemic adverse effects. J Toxicol Cut Ocul Toxicol, 1990;9:131-47.